A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon)
- PMID: 10362894
- DOI: 10.1046/j.1468-1331.1999.640423.x
A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon)
Abstract
Rivastigmine is a carbamate acetylcholinesterase (AChE) inhibitor with central selectivity. Early studies showed that daily doses up to 6 mg/day have some efficacy in patients with dementia of the Alzheimer type (DAT). The present study was designed to assess the safety, tolerability and efficacy of rivastigmine at doses up to 12 mg/day. A total of 114 patients with mild-moderate DAT were randomly assigned to either rivastigmine (b.i.d. (twice daily) or t.i.d. (three times daily)) or placebo in a double-blind fashion titrated to their maximum tolerated dose over 10 weeks followed by an eight-week maintenance phase. The mean maximum tolerated dose was approximately 10 mg/day (b.i.d. or t.i.d.). Gastrointestinal complaints, the majority of which were mild to moderate, were the most frequently reported adverse events. No clinically relevant changes in vital signs, haematology or organ function were detected. Significantly more patients taking rivastigmine b.i.d. were considered improved according to the Clinicians' Interview-Based Impression of Change-Plus (CIBIC-Plus) vs. placebo (57% vs. 16%, respectively; P = 0.027). The Nurses' Observation Scale for Geriatric Patients (NOSGER) (memory component) and the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) also improved in the rivastigmine b.i.d. group vs. placebo (mean change from baseline on NOSGER = -0.7 vs. +1.3, respectively; P = 0.037: mean change from baseline on ADAS-cog = -2.7 vs. +0.2, respectively; P = 0.054). Despite the relatively small size and limited duration of the study, the finding that rivastigmine induced changes in the same (positive) direction in all three dimensions measured suggests that rivastigmine at doses of up to 12 mg/day has useful efficacy in patients with mild-moderate DAT. Reports from larger phase III studies confirm this finding. The results of this study also suggest that b.i.d. is the more efficacious regimen and has comparable tolerability to the t.i.d. regimen.
Copyright Lippincott Williams & Wilkins
Similar articles
-
Rivastigmine for Alzheimer's disease.Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191. doi: 10.1002/14651858.CD001191.pub2. Cochrane Database Syst Rev. 2009. Update in: Cochrane Database Syst Rev. 2015 Apr 10;(4):CD001191. doi: 10.1002/14651858.CD001191.pub3. PMID: 19370562 Updated. Review.
-
Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.Arch Neurol. 2003 Jun;60(6):843-8. doi: 10.1001/archneur.60.6.843. Arch Neurol. 2003. PMID: 12810489 Clinical Trial.
-
Rivastigmine for Alzheimer's disease.Cochrane Database Syst Rev. 2000;(4):CD001191. doi: 10.1002/14651858.CD001191. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2009 Apr 15;(2):CD001191. doi: 10.1002/14651858.CD001191.pub2. PMID: 11034705 Updated. Review.
-
An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors.Eur J Neurol. 2000 Mar;7(2):159-69. doi: 10.1046/j.1468-1331.2000.00046.x. Eur J Neurol. 2000. PMID: 10809936 Clinical Trial.
-
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.BMJ. 1999 Mar 6;318(7184):633-8. doi: 10.1136/bmj.318.7184.633. BMJ. 1999. PMID: 10066203 Free PMC article. Clinical Trial.
Cited by
-
Alzheimer's Disease: Models and Molecular Mechanisms Informing Disease and Treatments.Bioengineering (Basel). 2024 Jan 1;11(1):45. doi: 10.3390/bioengineering11010045. Bioengineering (Basel). 2024. PMID: 38247923 Free PMC article. Review.
-
Novel 3-aminobenzofuran derivatives as multifunctional agents for the treatment of Alzheimer's disease.Front Chem. 2022 Aug 9;10:882191. doi: 10.3389/fchem.2022.882191. eCollection 2022. Front Chem. 2022. PMID: 36017161 Free PMC article.
-
The Dose and Duration-dependent Association between Melatonin Treatment and Overall Cognition in Alzheimer's Dementia: A Network Meta- Analysis of Randomized Placebo-Controlled Trials.Curr Neuropharmacol. 2022;20(10):1816-1833. doi: 10.2174/1570159X20666220420122322. Curr Neuropharmacol. 2022. PMID: 35450525 Free PMC article.
-
Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia.Drugs Aging. 2021 Jul;38(7):593-602. doi: 10.1007/s40266-021-00863-5. Epub 2021 May 24. Drugs Aging. 2021. PMID: 34027602
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2021 Jan 12;51(1):8-58. Psychopharmacol Bull. 2021. PMID: 33897062 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical